Orchard Therapeutics (Orchard Therapeutics) Net Margin % : -560.44% (As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Orchard Therapeutics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Orchard Therapeutics's Net Income for the three months ended in Sep. 2023 was $-35.32 Mil. Orchard Therapeutics's Revenue for the three months ended in Sep. 2023 was $6.30 Mil. Therefore, Orchard Therapeutics's net margin for the quarter that ended in Sep. 2023 was -560.44%.

The historical rank and industry rank for Orchard Therapeutics's Net Margin % or its related term are showing as below:

ORTX' s Net Margin % Range Over the Past 10 Years
Min: -11102.84 Med: -6503.06 Max: -333.9
Current: -333.9

ORTX's Net Margin % is not ranked
in the Biotechnology industry.
Industry Median: -155.475 vs ORTX: -333.90

Orchard Therapeutics Net Margin % Historical Data

The historical data trend for Orchard Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orchard Therapeutics Net Margin % Chart

Orchard Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Net Margin %

Get a 7-Day Free Trial

-11,102.84

-6,503.06

-5,856.61

-8,631.88

-665.02

Orchard Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Net Margin %	Get a 7-Day Free Trial															-823.35	-112.84	-1,407.60	-168.27	-560.44

Competitive Comparison of Orchard Therapeutics's Net Margin %

For the Biotechnology subindustry, Orchard Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Orchard Therapeutics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orchard Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Orchard Therapeutics's Net Margin % falls into.

Orchard Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Orchard Therapeutics's Net Margin for the fiscal year that ended in Dec. 2022 is calculated as

Net Margin	=	Net Income (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-150.66	/	22.655
	=	-665.02 %

Orchard Therapeutics's Net Margin for the quarter that ended in Sep. 2023 is calculated as

Net Margin	=	Net Income (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	-35.319	/	6.302
	=	-560.44 %

Orchard Therapeutics (NAS:ORTX) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Orchard Therapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of Orchard Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Orchard Therapeutics (Orchard Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orchard Therapeutics PLC (NAS:ORTX) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

OT10:Germany

Address

245 Hammersmith Road, London, GBR, W6 8PW

Website

https://www.orchard-tx.com

Orchard Therapeutics PLC is a United Kingdom-based commercial-stage, a fully-integrated biopharmaceutical company. The company is engaged in transforming the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. It operates in three geographic regions: the United Kingdom, European Union, and the United States. Orchard Rx is focusing on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, used for the treatment of ADA-SCID five lentiviral product candidates.

Executives

Bobby Gaspar	director, officer: See Remarks	ORCHARD THERAPEUTICS PLC, 108 CANNON STREET, LONDON X0 EC4N 6EU
Fmr Llc	10 percent owner, other: See Remark 1	245 SUMMER STREET, BOSTON MA 02210
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p.	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rajeev M. Shah	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Steven Altschuler	director	MEAD JOHNSON NUTRITION COMPANY, 2701 PATRIOT BLVD, GLENVIEW IL 60026
Jon Ellis	director	ORCHARD THERAPEUTICS PLC, 108 CANNON STREET, LONDON X0 EC4N 6EU
Plc Glaxosmithkline	director, 10 percent owner	980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Marc Dunoyer	director	ORCHARD THERAPEUTICS PLC, 108 CANNON STREET, LONDON X0 EC4N 6EU
John T Curnutte	director	PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Rowland Charles A Jr	director	3338 LANCASHIRE RD, FURLONG PA 18925
Mark Rothera	director, officer: See Remarks	C/O AEGERION PHARMACEUTICALS, INC., 101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
James A Geraghty	director	C/O IDERA PHARMACEUTICALS, INC., 167 SIDNEY STREET, CAMBRIDGE MA 02139
Alicia Secor	director	33 HAYDEN AVE., LEXINGTON MA 02421